Halozyme Therapeutics, Inc. (HALO) is a publicly traded Healthcare sector company. As of May 21, 2026, HALO trades at $69.47 with a market cap of $8.00B and a P/E ratio of 23.31. HALO moved +0.36% today. Year to date, HALO is -3.12%; over the trailing twelve months it is +29.06%. Its 52-week range spans $42.01 to $82.22. Analyst consensus is strong buy with an average price target of $84.48. Rallies surfaces HALO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading HALO stock inside the company?
Recent HALO insider activity includes Torley Helen sold 2.10K, Torley Helen sold 3.35K, Torley Helen sold 3.95K, Torley Helen sold 600, and Torley Helen sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.
HALO Key Metrics
Key financial metrics for HALO
Metric
Value
Price
$69.47
Market Cap
$8.00B
P/E Ratio
23.31
EPS
$2.96
Dividend Yield
0.00%
52-Week High
$82.22
52-Week Low
$42.01
Volume
266
Avg Volume
0
Revenue (TTM)
$1.51B
Net Income
$348.84M
Gross Margin
82.79%
Recent HALO Insider Trades
Torley Helen sold 2.10K (~$143.01K) on May 13, 2026.
Torley Helen sold 3.35K (~$230.75K) on May 13, 2026.
Torley Helen sold 3.95K (~$275.66K) on May 13, 2026.
Recent HALO insider activity includes Torley Helen sold 2.10K, Torley Helen sold 3.35K, Torley Helen sold 3.95K, Torley Helen sold 600, and Torley Helen sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for HALO?
Yes. Rallies tracks HALO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is HALO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HALO. It does not provide personalized investment advice.
